Arbutus Biopharma Corporation (NASDAQ:ABUS) Sellers Declined By 3.96% Their Shorts

April 17, 2018 - By Elizabeth Jones

Arbutus Biopharma Corporation (NASDAQ:ABUS) Corporate Logo

It was recorded a decrease on Arbutus Biopharma Corporation (NASDAQ:ABUS)’s shares shorted with 3.96%. FINRA announced shares shorted of ABUS’s total 638,600 shares. The down change of 3.96% from 664,900 shares was reported. Arbutus Biopharma Corporation (NASDAQ:ABUS) has 262,500 shares average volume. It’ll cost 2 days for ABUS to restore its former position. 2.12% is Arbutus Biopharma Corporation float short.

ABUS reached $5.25 on during the last trading session after $0.05 change.Currently Arbutus Biopharma Corporation is uptrending after 60.00% change in last April 17, 2017. ABUS has 130,049 shares volume. ABUS outperformed the S&P500 by 48.45%.

Arbutus Biopharma Corporation, a biopharmaceutical company, engages in discovering, developing, and commercializing a cure for patients suffering from chronic Hepatitis B virus infection in Canada and the United States.The firm is valued at $289.12 million. It also develops a pipeline of products based on RNA interference therapeutics (RNAi).Currently it has negative earnings. The companyÂ’s lead candidate is ARB-1467, which is in a Phase II trial to eliminate HBV surface antigen expression in patients chronically infected with HBV.

Arbutus Biopharma Corporation (NASDAQ:ABUS) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.